<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 47-year-old female patient with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease had been treated with <z:chebi fb="0" ids="23359">colchicine</z:chebi>, <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A, and infliximab </plain></SENT>
<SENT sid="1" pm="."><plain>Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started </plain></SENT>
<SENT sid="2" pm="."><plain>This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity </plain></SENT>
<SENT sid="3" pm="."><plain>This experience indicates that tocilizumab may constitute a therapeutic option for refractory <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
</text></document>